CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Immunotherapy: the Mega Weapon to Cure Cancer.
Immunotherapy: the Mega Weapon to Cure Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
提出溶瘤病毒疗法是免疫检查点与 CAR-T 细胞疗法之间的桥梁,可对癌症产生更有效、更特异的免疫应答。
癌症是最复杂的基因组疾病之一,能够获得抵抗不同疗法的能力。这些能力被称为癌症的标志性特征,使得免疫疗法等特异性及个体化疗法成为可能。
本文综述了不同的免疫疗法,如免疫检查点阻断、嵌合抗原受体(CAR)T细胞和溶瘤病毒疗法,目前正在使用和研究这些疗法,通过利用患者的免疫系统来克服癌细胞的能力。
免疫检查点阻断疗法通过使用抗PD-1受体和抗CTLA-4受体抗体来阻断免疫抑制通路,使淋巴细胞对癌细胞更具反应性。随后,讨论了如何设计CAR-T 细胞,使癌细胞抗原更容易被T细胞识别,从而实现更特异性的免疫反应。此外,研究表明溶瘤病毒可直接破坏癌细胞,并间接使癌细胞对免疫系统更易感。
Cancer is one of the most complex genomic diseases that can gain abilities to resist different therapies. These capabilities, known as the hallmark of cancer, allow specific and personalised therapies such as immunotherapy.
This review paper discusses how different immunotherapies, such as immune checkpoint blockade, chimeric antigen receptor (CAR) T-cell, and Oncolytic viral therapy, which are currently being used and researched to overcome cancer cell capabilities by using the patient's immune system.
Immune checkpoint blockade therapy is used to block immune inhibitory pathways using anti-PD-1 receptor and anti-CTLA-4 receptor antibodies, which make lymphocytes more responsive towards cancer cells. Then, it is discussed how CAR T-cells are designed to make cancer antigens more easily identified by T-cells for a more specific immune response. Furthermore, it is shown that oncolytic viruses directly destroy cancer cells and, indirectly, make them more vulnerable to the immune system.
It is proposed that oncolytic viral therapy is a bridge between Immune checkpoint and CAR T-cell therapies for a more effective and more specific immune response towards cancer.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。